Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.65 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.65 |
| ▸ | JAK2 | O60674 | 2/20 | 0.65 |
| ▸ | FLT3 | P36888 | 2/20 | 0.65 |
| ▸ | BTK | Q06187 | 2/20 | 0.65 |
| ▸ | ITK | Q08881 | 2/20 | 0.65 |
| ▸ | CDC7 | O00311 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | PAK4 | O96013 | 1/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979671 | 0.93 | ALK (0.68) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL1532357 | 0.93 | EGFR (0.68) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL12628010 | 0.90 | ALK (0.64) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL1532325 | 0.87 | ALK (0.76) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL1817737 | 0.86 | ALK (0.64) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL12840738 | 0.86 | JAK3 (0.58) | EGFRPTK2JAK2FLT3BTK | |
| SCHEMBL1817282 | 0.85 | EGFR (0.68) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL12628011 | 0.84 | ALK (0.71) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL2592584 | 0.84 | MAPK3 (0.71) | EGFRPTK2MAPK8MAPK9MAPK10 | |
| SCHEMBL12627327 | 0.82 | ALK (0.79) | EGFRPTK2MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2478361-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | Avila Therapeutics, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | EGFR 479/4885PTK2 66/4885MAPK8 214/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | EGFR 479/4885PTK2 66/4885MAPK8 214/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | EGFR 486/4885PTK2 71/4885MAPK8 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.